Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Capital Employed (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Return on Capital Employed for 7 consecutive years, with 0.53% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 2.0% to 0.53% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.53% through Dec 2025, down 2.0% year-over-year, with the annual reading at 0.47% for FY2025, 2.0% up from the prior year.
  • Return on Capital Employed hit 0.53% in Q4 2025 for Allogene Therapeutics, up from 0.54% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.18% in Q4 2021 to a low of 0.56% in Q2 2025.
  • Historically, Return on Capital Employed has averaged 0.41% across 5 years, with a median of 0.49% in 2023.
  • Biggest five-year swings in Return on Capital Employed: grew 13bps in 2021 and later fell -26bps in 2023.
  • Year by year, Return on Capital Employed stood at 0.18% in 2021, then plummeted by -135bps to 0.42% in 2022, then fell by -23bps to 0.51% in 2023, then dropped by 0bps to 0.51% in 2024, then dropped by -3bps to 0.53% in 2025.
  • Business Quant data shows Return on Capital Employed for ALLO at 0.53% in Q4 2025, 0.54% in Q3 2025, and 0.56% in Q2 2025.